Literature DB >> 27431335

Imaging: PSMA PET-CT in initial prostate cancer staging.

Frederik A Verburg1, Andreas Pfestroff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27431335     DOI： 10.1038/nrurol.2016.136

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer.

Authors:  Jean-Baptiste Pinaquy; Henri De Clermont-Galleran; Gilles Pasticier; Gerald Rigou; Nicolas Alberti; Elif Hindie; Yacoub Mokrane; Philippe Fernandez
Journal:  Prostate       Date:  2014-11-12       Impact factor: 4.104

2.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Authors:  Tobias Maurer; Jürgen E Gschwend; Isabel Rauscher; Michael Souvatzoglou; Bernhard Haller; Gregor Weirich; Hans-Jürgen Wester; Matthias Heck; Hubert Kübler; Ambros J Beer; Markus Schwaiger; Matthias Eiber
Journal:  J Urol       Date:  2015-12-09       Impact factor: 7.450

3.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

4.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

5.  Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.

Authors:  Pim J van Leeuwen; Louise Emmett; Bao Ho; Warick Delprado; Francis Ting; Quoc Nguyen; Phillip D Stricker
Journal:  BJU Int       Date:  2016-06-18       Impact factor: 5.588

6.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Authors:  Matthias Eiber; Gregor Weirich; Konstantin Holzapfel; Michael Souvatzoglou; Bernhard Haller; Isabel Rauscher; Ambros J Beer; Hans-Jürgen Wester; Juergen Gschwend; Markus Schwaiger; Tobias Maurer
Journal:  Eur Urol       Date:  2016-01-18       Impact factor: 20.096

7.  Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

Authors:  Frederik A Verburg; David Pfister; Axel Heidenreich; Andreas Vogg; Natascha I Drude; Stefan Vöö; Felix M Mottaghy; Florian F Behrendt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-12       Impact factor: 9.236

8.  Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.

Authors:  H Rhee; P Thomas; B Shepherd; S Gustafson; I Vela; P J Russell; C Nelson; E Chung; G Wood; G Malone; S Wood; P Heathcote
Journal:  J Urol       Date:  2016-05-21       Impact factor: 7.450

9.  Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer.

Authors:  Kambiz Rahbar; Matthias Weckesser; Sebastian Huss; Axel Semjonow; Hans-Jörg Breyholz; Andres J Schrader; Michael Schäfers; Martin Bögemann
Journal:  J Nucl Med       Date:  2016-01-14       Impact factor: 10.057

10.  PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.

Authors:  Frederik L Giesel; H Fiedler; M Stefanova; F Sterzing; M Rius; K Kopka; J H Moltz; A Afshar-Oromieh; P L Choyke; U Haberkorn; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-11       Impact factor: 9.236
  10 in total
  2 in total

1.  Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.

Authors:  Liran Domachevsky; Hanna Bernstine; Natalia Goldberg; Meital Nidam; Onofrio A Catalano; David Groshar
Journal:  Eur Radiol       Date:  2019-07-22       Impact factor: 5.315

2.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.